Showing 1 to 10 of 18 Clinical Trials
|
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
|---|---|---|---|
|
A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colon Cancer
PERIOP-01 NCT01455831  Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Colon and Rectum |
Dr. Vicky Tagalakis Elena Shulikovsky 514-340-8222 poste 23703 |
|
A Pilot Study of Two Dose Escalation Strategies to Increase the Population of Complete Responders After Radiation Therapy in Rectal Cancer Patients.
Morpheus study (no surgery) NCT03051464 Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Colon and Rectum |
Dr. Té Vuong Emma Starr 514-340-8222 poste 28443 |
|
An open-label, multicenter, randomized phase 3 study of first-line encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of encorafenib and cetuximab plus chemotherapy in participants with metastatic BRAF V600E-mutant colorectal cancer
BREAKWATER (C4221015) NCT04607421 Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Colon and Rectum |
Dr. Petr Kavan Rhythm Sharma 514-340-8222 poste 28248 |
|
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer
INTRINSIC NCT04929223 Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Colon and Rectum |
Dr. Petr Kavan Daria Krutauz 514-340-8222 poste 24301 |
|
A phase 2, randomized, open-label study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated BRAF V600E-MUTANT, MSI H/DMMR metastatic colorectal cancer
SEAMARK NCT05217446 Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Colon and Rectum |
Dr. Petr Kavan Aline Mamo 514-340-8222 poste 5525 |
|
A phase 2, randomized, open-label study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated BRAF V600E-MUTANT, MSI H/DMMR metastatic colorectal cancer
SEAMARK NCT05217446 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Colon and Rectum |
Dr. Mikaël Soucisse Samara Bloom 514-252-3400 poste 6244 |
|
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
CRC10 (NRG-GI008) NCT05174169 Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
Colon and Rectum |
Dr. Vincent Barrette Pierre Bédard 418-835-7121 |
|
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
CRC10 (NRG-GI008) NCT05174169 Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Colon and Rectum |
Dr. Mélina Boutin Valérie Painchaud-Lachapelle 450-466-5000 poste 2278 |
|
A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK-3475) or MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer:
MK-1308A-008 NCT04895722 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Colon and Rectum |
Dr. Jamil Asselah Stephanie van Rensselaer 514-934-1934 poste 35738 |
|
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
AZUR-2 NCT05855200 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Colon and Rectum |
Dr. Jamil Asselah Ryan Liu 514-934-1934 poste 34905 |
Groupe d'étude en oncologie du Québec